BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BioCentury | Jan 13, 2017
Company News

Selten, Vivus deal

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford,...
BioCentury | Mar 21, 2016
Clinical News

THR-184: Phase II data

...and after surgery. Thrasos Therapeutics Inc. , Montreal, Quebec Product: THR-184 Business: Renal Molecular target: Bone morphogenetic protein receptors...
BioCentury | Oct 5, 2015
Company News

Vanderbilt University, La Jolla Pharmaceutical deal

La Jolla and the university partnered to develop small molecule kinase inhibitors discovered at the university, which selectively block members of the bone morphogenetic protein receptor type I (BMPRI) family. La Jolla will fund the...
BioCentury | Aug 10, 2015
Emerging Company Profile

New tac for modifying PAH

Selten Pharma Inc. is developing a new formulation of the generic immunosuppressive drug tacrolimus that activates the BMPRII pathway and could prevent or even reverse the deleterious vascular remodeling seen with pulmonary arterial hypertension. In...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Bone morphogenetic protein 9 (BMP9; GDF2); bone morphogenetic protein receptor type II (BMPRII)

Cardiovascular disease INDICATION: Hypertension Cell culture and mouse studies suggest BMP9 could help treat pulmonary arterial hypertension (PAH). Mutations in BMPRII have been associated with PAH pathogenesis. In assays in endothelial cells from PAH patients...
BioCentury | Apr 29, 2013
Clinical News

LJPC-6417 regulatory update

La Jolla said FDA granted Orphan Drug designation for its LJPC-6417 to treat fibrodysplasia ossificans progressiva, a rare inherited disorder where muscle and connective tissue are replaced by bone. The kinase inhibitor targeting bone morphogenetic...
BioCentury | Jul 19, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Bone morphogenetic protein 2 (BMP2); BMP4; bone morphogenetic protein receptor type IA (BMPR1A) In vitro and mouse studies suggest...
BioCentury | Oct 10, 2011
Product Development

Bone-free BMP

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties. BMP has been...
Items per page:
1 - 10 of 10